• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Strategic Partnerships and Acquisitions Prevail in the Rapidly Growing Specialty Pharmaceuticals Market

Posted on: Monday, 28 August 2006, 09:00 CDT

PALO ALTO, Calif., Aug. 28 /PRNewswire/ -- With dwindling pipelines and several generic drugs going off-patent, specialty pharmaceuticals are likely to face increased competition from "Big Pharma". There is significant synergy between several specialty pharmaceutical companies, driving market consolidation through mergers and acquisitions.

New analysis from Frost & Sullivan (http://www.pharma.frost.com/ ), Analysis of Top 10 Specialty Pharmaceutical Companies, finds that the top 10 specialty pharmaceutical companies earned revenues of $19.83 billion in 2005, up from $17.30 billion in 2004.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the Analysis of Top 10 Specialty Pharmaceutical Companies, then send an e- mail to Melina Trevino, Corporate Communications, at melina.trevino@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"There is a huge unmet need in several therapeutic markets, which can only be catered to with a focused approach driven by strategic partnerships between specialty pharmaceutical companies," notes Frost & Sullivan Research Analyst Barath Shankar S.

Strategic partnerships and launch of generics with cutting edge drug delivery technologies is the key to driving demand in the specialty pharmaceuticals markets.

Specialty pharmaceutical companies need to gear-up to face the challenge from "Big Pharma" companies. Furthermore, there is a risk of prolonged litigations over patents posing uncertainty over growth.

"With increased competition from 'Big Pharma' there is likely to be a significant threat to the top 10 specialty pharmaceutical companies, thus there is an urgent need to ensure competitiveness and growth to counter it," explains Shankar S.

The top 10 specialty pharmaceutical companies have shown strong growth and are likely to accelerate ahead through well-planned in-licensing and acquisition strategies. Consolidation in the market, through mergers and acquisitions, is likely to help these companies to compete with "Big Pharma" companies.

Analysis of top 10 specialty pharmaceutical companies is part of the pharmaceuticals and biotechnology subscription, which also includes research in the following markets: Strategic Analysis of U.S. Hepatitis B&C Markets, Global Vaccines Markets, Global Pharmaceutical Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com/ .

Analysis of Top 10 Specialty Pharmaceutical Companies F625-52 Contact: Melina Trevino Corporate Communications - North America P: 210.247.2440 F: 210.348.1003 E: melina.trevino@frost.com Radhika Menon Theodore Corporate Communications - Europe P: +91 (044) 42044541 E: rmtheodore@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: 65.6890.0937 F: 65.6890.0988 E: jkaur@frost.com Surbhi Dedhia Corporate Communications - India P: +91 22 2832 4705 Ext: 131 E: sdedhia@frost.com Sharmin Jassal Corporate Communications - Australia P: +61 2 8247 8900 F: +61 2 9252 8066 E: sharmin.jassal@frost.com http://www.frost.com/

Frost & Sullivan

CONTACT: Melina Trevino, Corporate Communications - North America,+1-210-247-2440, or fax, +1-210-348-1003, or melina.trevino@frost.com , orRadhika Menon Theodore, Corporate Communications - Europe, +91-044-42044541,or rmtheodore@frost.com , or Jasminder Kaur, Corporate Communications - AsiaPacific, +65-6890-0937, or fax, +65-6890-0988, or jkaur@frost.com , or SurbhiDedhia, Corporate Communications - India, +91-22-2832-4705, ext. 131, orsdedhia@frost.com , or Sharmin Jassal, Corporate Communications - Australia,+61-2-8247-8900, or fax, +61-2-9252-8066, or sharmin.jassal@frost.com , all ofFrost & Sullivan

Web site: http://www.frost.com/http://www.pharma.frost.com/

Source: PRNewswire

More News in this Category